Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Lung cancer : modern multidisciplinary management / / Henry S. Park, editor
| Lung cancer : modern multidisciplinary management / / Henry S. Park, editor |
| Pubbl/distr/stampa | [Place of publication not identified] : , : IntechOpen, , [2021] |
| Descrizione fisica | 1 online resource (224 pages) : illustrations |
| Disciplina | 616.99424 |
| Soggetto topico | Lungs - Cancer |
| ISBN | 1-78985-576-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Lung Cancer |
| Record Nr. | UNINA-9910490735503321 |
| [Place of publication not identified] : , : IntechOpen, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors
| Lung cancer : new understandings and therapies / / Anne C. Chiang, Roy S. Herbst, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana, , [2021] |
| Descrizione fisica | 1 online resource (263 pages) |
| Disciplina | 616.99424 |
| Collana | Current cancer research |
| Soggetto topico |
Lungs - Cancer
Lung Neoplasms - therapy Càncer de pulmó Quimioteràpia del càncer Radioteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-74028-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Chapter 1: Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- 1 Introduction -- 2 The Tumor Compartment -- 2.1 Immune Inhibitory Signals -- 2.2 Immune Suppressive Cytokines -- 2.3 Antigen Presentation Machinery Alterations -- 2.4 Altered Intracellular Signaling and Differentiation -- 3 The Stromal Compartment -- 3.1 Immune Cells in the Stroma -- 3.1.1 Adaptive Immune Cells: T Lymphocytes -- 3.1.2 Adaptive Immune Cells: B Lymphocytes -- 3.1.3 Innate Immune Cells: NK Cells -- 3.1.4 Innate Immune Cells: Myeloid Cells -- 3.2 Non-immune Cells in the Stroma -- 3.2.1 Non-immune Cells in the Stroma: Cancer Associated Fibroblasts (CAFs) -- 3.2.2 Non-immune Cells in the Stroma: Vascular Cells -- 3.3 Non-Cellular Elements of the TME: The Extracellular Matrix (ECM) -- 4 Biomarkers -- 4.1 Validated Biomarkers in the Tumor -- 4.1.1 PD-L1 Expression -- 4.1.2 Oncogenic Drivers -- 4.1.3 Tumor Mutational Burden -- 4.2 Validated Biomarkers in the Stroma -- 4.2.1 Tumor Infiltrating Lymphocytes (TILs) -- 4.2.2 T-Cell RNA Signatures -- 4.2.3 Developing Biomarkers -- Interferon Gamma Response Pathway -- Beta-2-Microglobulin Alterations -- DNA Sensing Alterations: LKB1 -- FBXW7 -- TGFß Pathway -- Activation of Alternative Immune Pathways -- Microbiome -- Immune Heterogeneity -- 5 Conclusions -- References -- Chapter 2: Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail? -- 1 Introduction -- 2 Definition of TMB and TMB Assessment Methods -- 3 TMB and Association with Response to ICIs -- 3.1 Pembrolizumab -- 3.2 Nivolumab -- 3.3 Atezolizumab -- 3.4 Durvalumab, Durvalumab Plus Tremelimumab -- 3.5 Nivolumab Plus Ipilimumab -- 3.6 Real-World Analyses -- 4 Efficacy of TMB as a Predictive Biomarker -- 5 Pragmatic Limitations -- 5.1 TMB Standardization -- 5.2 Feasibility of Assessing TMB in Routine Clinical Practice.
6 Biology Underlying the Response Association -- 7 Integrating TMB with Other Biomarkers of ICI Response -- 8 Conclusion -- References -- Chapter 3: Liquid Biopsies: New Technology and Evidence -- 1 Introduction -- 2 Circulating Tumor DNA -- 3 Initial Molecular Profiling in NSCLC -- 4 Detection of the Mechanism of Acquired Resistant to Targeted Therapy -- 5 Detection of Minimal Residual Disease -- 6 Small Cell Lung Cancer -- 7 Extracellular Vesicles -- 8 Circulating Tumor Cells -- 9 Conclusion -- References -- Chapter 4: Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- 1 Clinical Activity of Osimertinib -- 2 Activity in CNS and Leptomeningeal Disease -- 3 Osimertinib in the Adjuvant Setting -- 4 Resistance to Osimertinib -- 5 Conclusion -- References -- Chapter 5: Immune Therapy: What Can We Learn From Acquired Resistance? -- 1 Introduction -- 2 Defining Acquired Resistance -- 2.1 Classification Based on Initial Response -- 2.2 Acquired Resistance Versus Off-Therapy Progression -- 3 Clinical Observations in Patients with Advanced NSCLC and Acquired Resistance to PD-1 Axis Inhibitors -- 4 Concepts in the Management of Acquired Resistance to PD-1 Axis Inhibitors in Advanced NSCLC -- 4.1 Local Therapy -- 4.2 Resume/Re-Challenge with PD-1 Axis Inhibitor Therapy -- 4.3 PD-1 Axis Inhibitor Combinations -- 4.3.1 PD-1 Axis Inhibitors + CTLA-4 Inhibitors -- 4.3.2 Novel Combination Strategies for PD-1 Axis Inhibitor Relapsed/Refractory NSCLC -- PD-1 Axis Inhibitor + Interleukin Receptor Agonist -- PD-1 Axis Inhibitor + Histone Deacetylase Inhibitors (HDACi) -- PD-1 Axis Inhibitor + Adenosine A2A Receptor Antagonists -- PD-1 Axis Inhibitor + Sitravatinib -- PD-1 Axis Inhibitor + Anti-TIM-3 -- Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) +/− PD-1 Axis Inhibitor. 4.4 Chemotherapy Sensitization -- 5 Mechanisms Mediating Acquired Resistance to PD-1 Axis Inhibitors in NSCLC -- 5.1 Acquired Neoantigen Loss -- 5.2 Acquired Antigen Processing and Presentation Defects -- 6 Uncovering Mechanisms of IO-Acquired Resistance in Other Tumor Types -- 6.1 Acquired Defects in Interferon-Gamma (IFN- γ) Signaling and Antigen Presentation -- 6.2 Immune-Suppressive Changes in the Tumor Microenvironment -- 6.3 PTEN Loss -- 6.4 Novel Experimental Discoveries -- 6.5 Conclusions and Future Visions -- References -- Chapter 6: Management of Brain Metastases -- 1 Introduction -- 2 Local Treatments for Brain Metastases: The Historical Standard of Care -- 3 Challenges in the Use of Systemic Treatment for Brain Metastases -- 4 Systemic Therapies for Brain Metastases in NSCLC -- 4.1 Chemotherapy -- 4.2 Targeted Therapies -- 4.2.1 EGFR Mutations -- 4.2.2 ALK Rearrangements -- 4.2.3 Other Driver Mutations (ROS1, RET, BRAF, MET, NTRK) -- 4.3 Immunotherapy - Checkpoint Inhibitors -- 5 Conclusions -- References -- Chapter 7: Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1 Introduction -- 1.1 Clinical Scenario -- 1.2 Mechanism of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- 1.3 Incidence of IRAEs by Agent and in Combination -- 1.4 Biomarkers to Identify Patients at Risk for Developing IRAEs -- 2 Management of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors (ICPIs) -- 3 Organ Specific Immune-Related Adverse Events -- 3.1 Dermatologic -- 3.2 Gastrointestinal -- 3.3 Pulmonary -- 3.4 Endocrine -- 3.5 Hepatic -- 3.6 Renal -- 3.7 Cardiac -- 3.8 Neurologic -- 3.9 Musculoskeletal-Rheumatologic -- 3.10 Ocular -- 3.11 Hematologic -- 4 Summary -- References -- Chapter 8: Therapeutic Advances in Small Cell Lung Cancer Management -- 1 Introduction. 2 Limited Stage Small Cell Lung Cancer -- 2.1 Surgery for Limited Stage Small Cell Lung Cancer -- 2.2 Chemoradiation for Limited Stage Small Cell Lung Cancer -- 2.3 Checkpoint Inhibitors in Limited Stage Small Cell Lung Cancer -- 2.4 Prophylactic Cranial Radiation for Limited Stage Small Cell Lung Cancer -- 2.5 Surveillance After Initial Management of Limited Stage Small Cell Lung Cancer -- 3 Extensive Stage Small Cell Lung Cancer -- 3.1 Thoracic Irradiation as Consolidation Therapy -- 3.2 Prophylactic Cranial Radiation in Extensive Stage Small Cell Lung Cancer -- 4 Brain Metastasis -- 5 Treatment of Refractory and Relapsed Small Cell Lung Cancer -- 5.1 Checkpoint Inhibitor Therapy for Relapsed Disease -- 5.2 Chemotherapy for Relapsed Disease -- 5.3 Beyond the Second Line -- 6 Novel Treatments -- 6.1 DNA Repair -- 6.2 MYC Gene Family -- 6.3 Epigenetics -- 6.4 Other Approaches -- 7 Conclusion -- References -- Chapter 9: Small Cell Lung Cancer: Biology Advances -- 1 Introduction -- 2 Identifying Therapeutic Targets in SCLC -- 2.1 DNA Damage Response (DDR) Proteins -- 2.2 DDR Inhibition and Immunotherapy -- 2.3 MYC -- 2.4 Targets in Developmental Pathways -- 2.5 BCL2 -- 2.6 Epigenetic Inhibitors -- 3 Immunotherapy: Recent Approvals, Biomarkers and Novel Combinations -- 4 A New Classification System: SCLC Subtypes Based on Dominant Gene Expression Profile -- 5 Conclusions -- References -- Chapter 10: Immunotherapy and Radiotherapy: New Strategies -- 1 Introduction -- 2 Radiotherapy as In Situ Vaccine -- 2.1 Principles of Vaccination as Applied to NSCLC -- 2.2 Radiotherapy as Both Antigen and Adjuvant -- 3 Radiotherapy and the Innate Immune System -- 3.1 Immunogenic Cell Death -- 3.2 DNA Damage Machinery and Pattern Recognition Receptors: An Emerging Overlap -- 3.3 Recognition of DNA Damage with cGAS/STING -- 3.4 Recognition of DNA Damage with AIM2. 3.5 RAD51 at the Intersection of the DNA Damage Response and Innate Immunity -- 3.6 Radiotherapy and RNA Sensing: RIG-I -- 3.7 Type I IFN in Acute and Chronic Settings -- 3.8 Immunostimulatory Effects of Acute Type I IFN in Cancer -- 3.9 Immunosuppressive Effects of Chronic Type I IFN in Cancer -- 4 Radiotherapy and the Adaptive Immune System -- 4.1 Priming of the Adaptive Immune System -- 4.2 The Importance of Cross-Presentation in the Anti-tumoral Response -- 4.3 Radiotherapy and Immunological Memory -- 4.4 T Cell Exhaustion within the Tumor Microenvironment -- 4.5 Checkpoint Inhibition and Radiotherapy -- 5 Maximizing the Clinical Utility of Radiotherapy in an Era of Checkpoint Inhibition: New Strategies -- 5.1 Rational Treatment Design -- 5.2 Choice of Target -- 5.3 Timing -- 5.4 Dose and Fractionation -- 6 Conclusions -- References -- Chapter 11: Ultimate Precision: Targeting Cancer But Not Normal Self-Replication -- 1 Introduction -- 2 Replication and Lineage-Differentiation Are Linked -- 3 Dis-Engaging Replication from Advances Along a Lineage -- 4 The Importance of Reconciling These Different Models -- 5 Cell-of-Origin Versus Cell-of-Transformation -- 6 Master Transcription Factor Alterations in Cancer Cells -- 7 Targeting Cancer, But Not Normal, Self-Replication -- 8 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910502622503321 |
| Cham, Switzerland : , : Humana, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung Cancer / / edited by Henry S. Park
| Lung Cancer / / edited by Henry S. Park |
| Pubbl/distr/stampa | London, England : , : IntechOpen, , 2021 |
| Descrizione fisica | 1 online resource (224 pages) |
| Disciplina | 616.99424 |
| Soggetto topico |
Lungs - Cancer
Oncology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Lung Cancer |
| Record Nr. | UNINA-9910688593703321 |
| London, England : , : IntechOpen, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer / / editors, Daniel Morgensztern, [and three others]
| Lung cancer / / editors, Daniel Morgensztern, [and three others] |
| Pubbl/distr/stampa | Philadelphia, Pennsylvania : , : Elsevier, , 2017 |
| Descrizione fisica | 1 online resource (249 pages) : illustrations |
| Disciplina | 616.99424 |
| Collana | Hematology/Oncology Clinics of North America |
| Soggetto topico | Lungs - Cancer |
| ISBN | 0-323-49660-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910157396803321 |
| Philadelphia, Pennsylvania : , : Elsevier, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer / / edited by Jack A. Roth [and five others]
| Lung cancer / / edited by Jack A. Roth [and five others] |
| Edizione | [Fourth edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 |
| Descrizione fisica | 1 online resource (634 p.) |
| Disciplina | 616.99/424 |
| Soggetto topico |
Lungs - Diseases - Diagnosis
Lungs - Cancer - Treatment Lungs - Cancer Cancer - Diagnosis |
| ISBN |
1-118-46877-5
1-118-46879-1 1-118-46876-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Lung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline
Combination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways Emerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview Lung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References CHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies Clinical validation of serum biomarkers |
| Record Nr. | UNINA-9910132216103321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer / / edited by Jack A. Roth [and five others]
| Lung cancer / / edited by Jack A. Roth [and five others] |
| Edizione | [Fourth edition.] |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 |
| Descrizione fisica | 1 online resource (634 p.) |
| Disciplina | 616.99/424 |
| Soggetto topico |
Lungs - Diseases - Diagnosis
Lungs - Cancer - Treatment Lungs - Cancer Cancer - Diagnosis |
| ISBN |
1-118-46877-5
1-118-46879-1 1-118-46876-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Lung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline
Combination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways Emerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview Lung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References CHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies Clinical validation of serum biomarkers |
| Record Nr. | UNINA-9910818491303321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer [[electronic resource] /] / [edited by] Apar Kishor Ganti, David E. Gerber
| Lung cancer [[electronic resource] /] / [edited by] Apar Kishor Ganti, David E. Gerber |
| Pubbl/distr/stampa | New York, : Oxford University Press, 2013 |
| Descrizione fisica | 1 online resource (259 p.) |
| Disciplina | 616.99/424 |
| Altri autori (Persone) |
GantiApar K
GerberDavid E (Professor of medicine) |
| Collana | Oxford American oncology library |
| Soggetto topico |
Lungs - Cancer
Cancer |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-19-935919-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Preface; Acknowledgments; Contributors; 1 Lung Cancer Epidemiology, Etiology and Risk Factors; 2 Biology of Lung Cancer; 3 Pathology of Lung Cancer; 4 Lung Cancer Screening; 5 Clinical Manifestations of Lung Cancer; 6 Diagnostic Evaluation and Staging of Lung Cancer; 7 Early Stage Non-Small Cell Lung Cancer; 8 Locally Advanced Non-Small Cell Lung Cancer; 9 Metastatic Non-Small Cell Lung Cancer; 10 Special Populations; 11 Small Cell Lung Cancer; 12 Pulmonary Neuroendocrine Tumors; 13 Mesothelioma; 14 Supportive Care in Lung Cancer; Index; A; B; C; D; E; F; G; H; I; J; K; L; M
NO; P; Q; R; S; T; V; W; X; Z |
| Record Nr. | UNINA-9910463093903321 |
| New York, : Oxford University Press, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer [[electronic resource] /] / [edited by] Apar Kishor Ganti, David E. Gerber
| Lung cancer [[electronic resource] /] / [edited by] Apar Kishor Ganti, David E. Gerber |
| Pubbl/distr/stampa | New York, : Oxford University Press, 2013 |
| Descrizione fisica | 1 online resource (259 p.) |
| Disciplina | 616.99/424 |
| Altri autori (Persone) |
GantiApar K
GerberDavid E (Professor of medicine) |
| Collana | Oxford American oncology library |
| Soggetto topico |
Lungs - Cancer
Cancer |
| ISBN | 0-19-935919-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Preface; Acknowledgments; Contributors; 1 Lung Cancer Epidemiology, Etiology and Risk Factors; 2 Biology of Lung Cancer; 3 Pathology of Lung Cancer; 4 Lung Cancer Screening; 5 Clinical Manifestations of Lung Cancer; 6 Diagnostic Evaluation and Staging of Lung Cancer; 7 Early Stage Non-Small Cell Lung Cancer; 8 Locally Advanced Non-Small Cell Lung Cancer; 9 Metastatic Non-Small Cell Lung Cancer; 10 Special Populations; 11 Small Cell Lung Cancer; 12 Pulmonary Neuroendocrine Tumors; 13 Mesothelioma; 14 Supportive Care in Lung Cancer; Index; A; B; C; D; E; F; G; H; I; J; K; L; M
NO; P; Q; R; S; T; V; W; X; Z |
| Record Nr. | UNINA-9910787559003321 |
| New York, : Oxford University Press, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer : clinical and surgical specifications / / edited by Akin Eraslan Balci
| Lung cancer : clinical and surgical specifications / / edited by Akin Eraslan Balci |
| Pubbl/distr/stampa | Oak Park, Illinois : , : Bentham Science Publishers, , 2013 |
| Descrizione fisica | 1 online resource (620 p.) |
| Disciplina | 616.99424 |
| Altri autori (Persone) | BalciAkin Eraslan |
| Soggetto topico |
Lungs - Cancer - Treatment
Lungs - Cancer |
| ISBN | 1-60805-442-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chatper 01 Part A; Chatper 01 Part B; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Chatper 10 Part A; Chatper 10 Part B; Chatper 10 Part C; Chatper 10 Part D; Chatper 10 Part E; Chatper 10 Part F; Chatper 10 Part G; Chatper 10 Part H; Chatper 10 Part I; Chatper 10 Part J; Chatper 10 Part K; Chapter 11 Part A; Chapter 11 Part B; Chapter 11 Part C; Chapter 12; Chapter 13 Part A; Chapter 13 Part B; Chatper 14; Chapter 15; Chapter 16; Index; Back Cover |
| Record Nr. | UNINA-9910787323203321 |
| Oak Park, Illinois : , : Bentham Science Publishers, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Lung cancer : clinical and surgical specifications / / edited by Akin Eraslan Balci
| Lung cancer : clinical and surgical specifications / / edited by Akin Eraslan Balci |
| Pubbl/distr/stampa | Oak Park, Illinois : , : Bentham Science Publishers, , 2013 |
| Descrizione fisica | 1 online resource (620 p.) |
| Disciplina | 616.99424 |
| Altri autori (Persone) | BalciAkin Eraslan |
| Soggetto topico |
Lungs - Cancer - Treatment
Lungs - Cancer |
| ISBN | 1-60805-442-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Title; EUL; Contents; Foreword; Preface; List of Contributors; Chatper 01 Part A; Chatper 01 Part B; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Chatper 10 Part A; Chatper 10 Part B; Chatper 10 Part C; Chatper 10 Part D; Chatper 10 Part E; Chatper 10 Part F; Chatper 10 Part G; Chatper 10 Part H; Chatper 10 Part I; Chatper 10 Part J; Chatper 10 Part K; Chapter 11 Part A; Chapter 11 Part B; Chapter 11 Part C; Chapter 12; Chapter 13 Part A; Chapter 13 Part B; Chatper 14; Chapter 15; Chapter 16; Index; Back Cover |
| Record Nr. | UNINA-9910827429303321 |
| Oak Park, Illinois : , : Bentham Science Publishers, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Lungs - Cancer
(56)
- Lung Neoplasms (10)
- Cancer (6)
- Lungs - Cancer - Treatment (5)
- Oncology (4)